

# Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2028

<https://marketpublishers.com/r/MFE66A46BBDEN.html>

Date: January 2019

Pages: 100

Price: US\$ 6,250.00 (Single User License)

ID: MFE66A46BBDEN

## Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology and market outlook for the 7MM.

## MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Metastatic Renal Cell Carcinoma (mRCC) Understanding and Treatment Algorithm

The market report provides the overview of the Metastatic Renal Cell Carcinoma (mRCC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases

and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Metastatic Renal Cell Carcinoma (mRCC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

#### Metastatic Renal Cell Carcinoma (mRCC) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

#### Metastatic Renal Cell Carcinoma (mRCC) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Metastatic Renal Cell Carcinoma (mRCC) market.

#### Metastatic Renal Cell Carcinoma (mRCC) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

#### Metastatic Renal Cell Carcinoma (mRCC) Report Insights

Patient Population in Metastatic Renal Cell Carcinoma (mRCC)

Therapeutic Approaches in Metastatic Renal Cell Carcinoma (mRCC)

Metastatic Renal Cell Carcinoma (mRCC) Pipeline Analysis

Metastatic Renal Cell Carcinoma (mRCC) Market Size and Trends

Metastatic Renal Cell Carcinoma (mRCC) Market Opportunities

Impact of upcoming Therapies in Metastatic Renal Cell Carcinoma (mRCC)

## Metastatic Renal Cell Carcinoma (mRCC) Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

## Metastatic Renal Cell Carcinoma (mRCC) Report Assessment

Current Treatment Practices in Metastatic Renal Cell Carcinoma (mRCC)

Unmet Needs in Metastatic Renal Cell Carcinoma (mRCC)

Market Attractiveness

Market Drivers and Barriers

## KEY BENEFITS

The report will help to develop Business Strategies by understanding the trends shaping and driving the Metastatic Renal Cell Carcinoma (mRCC) market

Organize sales and marketing efforts by identifying the best opportunities for Metastatic Renal Cell Carcinoma (mRCC) market

To understand the future market competition in the Metastatic Renal Cell Carcinoma (mRCC) market.

## Contents

### **1. REPORT INTRODUCTION**

### **2. METASTATIC RENAL CELL CARCINOMA (MRCC) MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2016

2.2. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: METASTATIC RENAL CELL CARCINOMA (MRCC)**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM

4.3. Total Prevalent Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM – By Countries

### **5. EPIDEMIOLOGY OF METASTATIC RENAL CELL CARCINOMA (MRCC) BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

5.1.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

## 5.2. EU5

### 5.3. Assumptions and Rationale

### 5.4. Germany

#### 5.4.1. Assumptions and Rationale

#### 5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.4.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

### 5.5. France

#### 5.5.1. Assumptions and Rationale

#### 5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.5.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

### 5.6. Italy

#### 5.6.1. Assumptions and Rationale

#### 5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.6.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

### 5.7. Spain

#### 5.7.1. Assumptions and Rationale

#### 5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.7.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

### 5.8. United Kingdom

#### 5.8.1. Assumptions and Rationale

#### 5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

#### 5.8.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

### 5.9. Japan

#### 5.9.1. Assumptions and Rationale

- 5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
- 5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC)
- 5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC)
- 5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
- 5.9.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE METASTATIC RENAL CELL CARCINOMA (MRCC)**

## **8. MARKETED THERAPIES**

- 8.1. Drug A: Company
  - 8.1.1. Drug Description
  - 8.1.2. Mechanism of Action
  - 8.1.3. Regulatory Milestones
  - 8.1.4. Advantages & Disadvantages
  - 8.1.5. Product Profile
- 8.2. Drug B: Company
  - 8.2.1. Drug Description
  - 8.2.2. Mechanism of Action
  - 8.2.3. Regulatory Milestones
  - 8.2.4. Advantages & Disadvantages
  - 8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR METASTATIC RENAL CELL CARCINOMA (MRCC)**

- 11.1. Drug C: Company
  - 11.1.1. Drug Description
  - 11.1.2. Clinical Trials Details
  - 11.1.3. Safety and Efficacy Profile

- 11.1.4. Advantages & Disadvantages
- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company
  - 11.2.1. Drug Description
  - 11.2.2. Clinical Trials Details
  - 11.2.3. Safety and Efficacy Profile
  - 11.2.4. Advantages & Disadvantages
  - 11.2.5. Pipeline Development Activities
  - 11.2.6. Product Profile

## **12. METASTATIC RENAL CELL CARCINOMA (MRCC): 7MM MARKET ANALYSIS**

- 12.1. 7MM Market Size of Metastatic Renal Cell Carcinoma (mRCC)
- 12.2. 7MM Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC)
- 12.3. 7MM Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products

## **13. METASTATIC RENAL CELL CARCINOMA (MRCC): COUNTRY-WISE MARKET ANALYSIS**

- 13.1. United States
  - 13.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United States
  - 13.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United States
  - 13.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United States
  - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
  - 13.2.1. Germany
    - 13.2.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Germany
    - 13.2.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Germany
    - 13.2.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Germany
    - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.2. France
    - 13.2.2.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in France
    - 13.2.2.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma



(mRCC) in France

13.2.2.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Italy

13.2.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Italy

13.2.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Spain

13.2.4.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Spain

13.2.4.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom

13.2.5.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Japan

13.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Japan

13.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

## **14. MARKET DRIVERS**

## **15. MARKET BARRIERS**

## **16. APPENDIX**

## **17. REPORT METHODOLOGY**

17.1. Sources

## **18. DELVEINSIGHT CAPABILITIES**

## **19. DISCLAIMER**

## **20. ABOUT DELVEINSIGHT**

Indication Specific

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Table 7: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Table 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Table 12: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Table 14: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Table 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Table 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Table 17: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in

Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Table 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Table 22: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Table 27: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Table 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Table 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Table 32: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Table 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Table 37: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 42:7MM- Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 43:7MM- Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 45: United States-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 48: Germany-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 51: France-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 54: Italy-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 57: Spain-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 60:UK-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Table 63: Japan-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Figure 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Figure 7: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Figure 12: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Figure 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Figure 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Figure 17: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in

Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Figure 22: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Figure 27: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Figure 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Figure 32: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)

Figure 37: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2028)



Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 42:7MM- Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 45: United States-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 48: Germany-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 51: France-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 54: Italy-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 57: Spain-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 60:UK-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2028)

Figure 63: Japan-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2028)

## I would like to order

Product name: Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2028

Product link: <https://marketpublishers.com/r/MFE66A46BBDEN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MFE66A46BBDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

